Utama › Penyakit Crohn › Texas › Tyler
Kajian klinikal Penyakit Crohn di Tyler, TX
16 kajian untuk Penyakit Crohn sedang mencari peserta di lokasi dalam dan sekitar Tyler (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Mengambil pesertaFasa 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Mengambil pesertaFasa 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Mengambil pesertaFasa 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Mengambil pesertaFasa 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Mengambil pesertaFasa 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Mengambil pesertaFasa 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Mengambil pesertaFasa 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Mengambil pesertaFasa 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Mengambil pesertaFasa 2
- Mirador Therapeutics Selected Site, Tyler
Kajian Penyakit Crohn di bandar lain
- New York City, NY35 kajian
- Cleveland, OH19 kajian
- St. Louis, MO19 kajian
- Boston, MA19 kajian
- Miami, FL19 kajian
- Orlando, FL17 kajian
- Houston, TX17 kajian
- Atlanta, GA17 kajian
- San Diego, CA15 kajian
- San Antonio, TX15 kajian
- Los Angeles, CA15 kajian
- Philadelphia, PA13 kajian
Kajian lain di Tyler
- Kanser Paru-paru Bukan Sel Kecil20 kajian
- Kolitis Ulseratif14 kajian
- Kanser Kolorektal8 kajian
- Kegagalan Jantung8 kajian
- Kanser (semua jenis)7 kajian
- Kanser Ovari7 kajian
- Kanser Endometrium6 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher6 kajian
- Kanser Payudara6 kajian
- Kanser Metastatik5 kajian
- Penyakit Usus Radang5 kajian
- Leukemia Limfositik Kronik5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.